Express Scripts / Evernorth

Overview

Evernorth Health Services is the health services subsidiary of The Cigna Group and the organizational umbrella under which Express Scripts, Accredo, CuraScript SD, eviCore, and MDLIVE operate. For pharma manufacturers, Evernorth is a vertically integrated intermediary controlling the full specialty drug value chain: formulary access decisions, specialty pharmacy dispensing, physician-office distribution, and hub/patient support services — all within a single corporate family.

The Evernorth brand launched in September 2020 following Cigna’s $67 billion acquisition of Express Scripts in December 2018. Approximately 90% of Evernorth’s business comes from external clients rather than Cigna’s own health plan, distinguishing it from more captive PBM models.

Express Scripts is the #1 ranked PBM by adjusted prescription claims volume, processing 2.22 billion adjusted claims in 2025 (up 4.8% YoY). The Big Three PBMs — Express Scripts, CVS Caremark, and OptumRx — collectively account for approximately 80% of all U.S. equivalent prescription claims.

Services & Capabilities

Express Scripts PBM — Formulary Management

Manages pharmacy benefits through formulary design, drug utilization review, rebate negotiation, and network-pharmacy claims adjudication. The National Preferred Formulary (NPF) covers 600+ excluded products by 2025. Formulary exclusion has evolved into Express Scripts’ most potent manufacturer negotiating tool — the default has shifted from open formulary to exclusion by default.

Ascent Health Services (GPO): Aggregates rebate negotiating power across Express Scripts, Prime Therapeutics, Humana Commercial, and other clients. FTC February 2026 settlement requires Ascent to relocate from Switzerland to the U.S.

Rebate-free model transition (October 2025): Shift to passing manufacturer discounts directly to members at point of sale. Timeline: fully insured Cigna plans in 2027; standard for all Express Scripts clients in 2028. Member co-pays cannot exceed net drug cost; formulary design must be WAC-neutral.

Accredo Specialty Pharmacy

The largest specialty pharmacy by dispensing volume in the U.S. Operates 15 disease-specific Therapeutic Resource Centers with 500+ specialty pharmacists and 600+ nurses/support staff. Key metrics: $2.8B in copay assistance coordinated (2024), $102M in specialty pharmacy savings, 3.1M clinical/compliance interactions annually. Serves all top 25 U.S. health plans. The “open” specialty pharmacy model — serving patients covered by rival PBMs — is a core revenue driver and structural competitive advantage.

CuraScript SD — Specialty Distribution

Distributes specialty pharmaceuticals to physician offices, infusion centers, surgery centers, and hospital outpatient departments (buy-and-bill channel, medical benefit). Distribution centers in Ohio, Tennessee, Delaware, and Arizona with 200,000+ sq ft, 99.9% order accuracy. Competes with McKesson Specialty Health, Cardinal Health Specialty Solutions, and Cencora.

eviCore — Medical Benefit Management

Prior authorization and utilization management for specialty drugs under the medical benefit (oncology infusions, gene therapies, high-cost injectables). Works across a large number of health plan clients beyond Cigna, making policy positions influential across a significant share of commercially insured lives.

Accumulator and Maximizer Programs

Administers both copay accumulator adjustment programs (CAAPs) and copay maximizer programs. Under accumulators, manufacturer copay assistance does not count toward deductible/OOP maximum. Under maximizers, the plan extracts the full value of manufacturer copay programs. 34% of large employer plans (5,000+ workers) have a copay accumulator program as of 2024.

Competitive Position

vs. CVS Caremark

Dimension	Express Scripts / Evernorth	CVS Caremark
PBM claims share (2025)	#1 at 2.22B adj. claims	#2, declining
Specialty pharmacy	Accredo (external client focus)	CVS Specialty (integrated, retail-anchored)
Retail network	No owned retail pharmacy	~9,000 CVS retail stores
Private label biosimilar	Quallent Pharmaceuticals	Cordavis
Distributor	CuraScript SD	No standalone specialty distributor
GPO	Ascent Health Services	Zinc Health Services
Medical benefit mgmt.	eviCore	No direct equivalent at scale

vs. OptumRx

OptumRx at ~23% claims share. UnitedHealth’s integrated payer-PBM-provider model provides deeper data integration but heightened antitrust scrutiny. DOJ scrutiny of UnitedHealth’s vertical integration is a wildcard.

Recent Developments

• Centene Contract Win (January 2024): Five-year PBM contract covering ~20M members from CVS Caremark. Elevated Express Scripts’ claims share from ~23% to ~30%.
• Cigna-Humana Merger Collapse (November 2024): Unable to agree on price; Cigna launched $11.3B share repurchase instead.
• Medicare Advantage Divestiture (March 2025): $3.7B sale to HCSC. Cigna retained PBM/pharmacy services relationship.
• Rebate-free Model (October 2025): Transition away from traditional rebate model; critics characterize as “head fake.”
• FTC Settlement (February 2026): Landmark consent order: member co-pays capped at net drug cost, spread pricing eliminated, Ascent relocated to U.S., 10-year compliance monitor. Estimated $7B patient savings.
• Shields Health Solutions Investment (September 2025): $3.5B preferred equity in health system specialty pharmacy integrator (80+ health systems, 1,000+ hospitals).
• Consolidated Appropriations Act, 2026: 100% rebate pass-through in Part D, spread pricing banned, any-willing-pharmacy provisions by 2028-2029.

Financial Profile

The Cigna Group — FY2024: Total revenues $247.1B (+27% YoY). Adjusted income from operations $7.7B ($27.33/share).

Evernorth Health Services — FY2024: Adjusted revenues ~$202B (+32% YoY). Pre-tax adjusted operating income $7.0B (+9% YoY). Pharmacy Benefit Services revenue +46% YoY. Evernorth contributed approximately 82% of Cigna Group’s total 2024 revenues.

Revenue growth was volume-driven (Centene contract) rather than price-driven, with compressed per-member profitability to win/retain volume. Specialty pharmacy accounts for approximately 40% of Evernorth revenues. Q2 2025 revenues reached $67.2B (Cigna Group), up 11% YoY.

Sources

Primary source: raw/research/03_express_scripts_evernorth.md. Financial data from Cigna Group investor relations and SEC filings. Market data from Drug Channels Institute, KFF, Goodwin Law, IntuitionLabs.